2025: John F. Crowley, MBA, JD

John F. Crowley is the President and CEO of the Biotechnology Innovation Organization (BIO), the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. Crowley, a longtime BIO board member, was previously the Founder and Executive Chairman of Amicus Therapeutics, a global biotechnology company focusing on developing treatments for rare genetic diseases. He served as Chief Executive Officer of Amicus from 2005 to 2022. 

John’s decades of biotech experience and deep passion for the field have made him a strong supporter of policies that empower innovation, enable entrepreneurship, and put people and patients first. His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, John left his position at Bristol Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation, where John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.